Literature DB >> 19735863

Radiation therapy for esophageal cancer in Japan: results of the Patterns of Care Study 1999-2001.

Masahiro Kenjo1, Takashi Uno, Yuji Murakami, Yasushi Nagata, Masahiko Oguchi, Susumu Saito, Hodaka Numasaki, Teruki Teshima, Michihide Mitsumori.   

Abstract

PURPOSE: To describe patient characteristics and the process of radiotherapy (RT) for patients with esophageal cancer treated between 1999 and 2001 in Japan. METHODS AND MATERIALS: The Japanese Patterns of Care Study (PCS) Working Group conducted a third nationwide survey of 76 institutions. Detailed information was accumulated on 621 patients with thoracic esophageal cancer who received RT.
RESULTS: The median age of patients was 68 years. Eighty-eight percent were male, and 12% were female. Ninety-nine percent had squamous cell carcinoma histology. Fifty-five percent had the main lesion in the middle thoracic esophagus. Fourteen percent had clinical Stage 0-I disease, 32% had Stage IIA-IIB, 43% had Stage III, and 10% had Stage IV disease. Chemotherapy was given to 63% of patients; 39% received definitive chemoradiotherapy (CRT) without surgery and 24% pre- or postoperative CRT. Sixty-two percent of the patients aged > or =75 years were treated with RT only. Median total dose of external RT was 60 Gy for definitive CRT patients, 60 Gy for RT alone, and 40 Gy for preoperative CRT.
CONCLUSIONS: This PCS describes general aspects of RT for esophageal cancer in Japan. Squamous cell carcinoma accounted for the majority of patients. The standard total external RT dose for esophageal cancer was higher in Japan than in the United States. Chemoradiotherapy had become common for esophageal cancer treatment, but patients aged > or =75 years were more likely to be treated by RT only.

Entities:  

Mesh:

Year:  2009        PMID: 19735863     DOI: 10.1016/j.ijrobp.2009.03.073

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).

Authors:  Yasumasa Nishimura; Keiichi Jingu; Satoshi Itasaka; Yoshiharu Negoro; Yuji Murakami; Katsuyuki Karasawa; Gen Kawaguchi; Fumiaki Isohashi; Masao Kobayashi; Yoshiyuki Itoh; Takuro Ariga
Journal:  Int J Clin Oncol       Date:  2015-07-16       Impact factor: 3.402

2.  Expression profile of apoptosis-related genes potentially explains early recurrence after definitive chemoradiation in esophageal squamous cell carcinoma.

Authors:  Yongshun Chen; Ying Wang; Haixia Song; Jin Wang; Haijun Yang; Yubing Xia; Jianxin Xue; Shidong Li; Ming Chen; You Lu
Journal:  Tumour Biol       Date:  2014-01-09

3.  Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303.

Authors:  Naoko Sanuki; Satoshi Ishikura; Masayuki Shinoda; Yoshinori Ito; Kazushige Hayakawa; Nobutoshi Ando
Journal:  Int J Clin Oncol       Date:  2011-06-14       Impact factor: 3.402

4.  Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey.

Authors:  Yasumasa Nishimura; Ryuta Koike; Kazuhiko Ogawa; Ryuta Sasamoto; Yuji Murakami; Yoshiyuki Itoh; Yoshiharu Negoro; Satoshi Itasaka; Toru Sakayauchi; Tetsuro Tamamoto
Journal:  Int J Clin Oncol       Date:  2011-05-25       Impact factor: 3.402

5.  Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan.

Authors:  Keiichi Jingu; Rei Umezawa; Haruo Matsushita; Toshiyuki Sugawara; Masaki Kubozono; Takaya Yamamoto; Youjirou Ishikawa; Maiko Kozumi; Noriyoshi Takahashi; Yu Katagiri; Noriyuki Kadoya; Ken Takeda
Journal:  Int J Clin Oncol       Date:  2015-09-01       Impact factor: 3.402

6.  Outcomes of patients with stage IVA esophageal cancer (Japanese classification) treated with definitive chemoradiotherapy.

Authors:  Akira Anbai; Makoto Koga; Satoru Motoyama; Mario Jin; Hiroyuki Shibata; Manabu Hashimoto
Journal:  Jpn J Radiol       Date:  2013-02-02       Impact factor: 2.374

7.  Intrafraction esophageal motion in patients with clinical T1N0 esophageal cancer.

Authors:  Shuhei Sekii; Yoshinori Ito; Ken Harada; Mayuka Kitaguchi; Kana Takahashi; Koji Inaba; Naoya Murakami; Hiroshi Igaki; Ryohei Sasaki; Jun Itami
Journal:  Rep Pract Oncol Radiother       Date:  2018-08-13

8.  Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.

Authors:  Kenji Nemoto; Shohei Kawashiro; Yasushi Toh; Hodaka Numasaki; Yuji Tachimori; Takashi Uno; Keiichi Jingu; Hisahiro Matsubara
Journal:  Esophagus       Date:  2020-01-07       Impact factor: 4.230

Review 9.  Management of elderly patients with esophageal squamous cell cancer.

Authors:  Yasuo Hamamoto; Kentaro Murakami; Ken Kato; Yuko Kitagawa
Journal:  Jpn J Clin Oncol       Date:  2022-08-05       Impact factor: 2.925

10.  Prognosis was not deteriorated by multiple primary cancers in esophageal cancer patients treated by radiotherapy.

Authors:  Katsuyuki Shirai; Yoshio Tamaki; Yoshizumi Kitamoto; Kazutoshi Murata; Yumi Satoh; Keiko Higuchi; Hitoshi Ishikawa; Tetsuo Nonaka; Takeo Takahashi; Takashi Nakano
Journal:  J Radiat Res       Date:  2013-02-04       Impact factor: 2.724

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.